AAAAAA
Results: 76-91/91
Authors:
Brin, MF
Lew, MF
Adler, CH
Comella, CL
Factor, SA
Jankovic, J
O'Brien, C
Murray, JJ
Wallace, JD
Willmer-Hulme, A
Koller, M
Citation: Mf. Brin et al., Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, NEUROLOGY, 53(7), 1999, pp. 1431-1438
Authors:
Hanna, PA
Janjua, FN
Contant, CF
Jankovic, J
Citation: Pa. Hanna et al., Bilineal transmission in Tourette syndrome, NEUROLOGY, 53(4), 1999, pp. 813-818
Authors:
Chokroverty, S
Jankovic, J
Citation: S. Chokroverty et J. Jankovic, Restless legs syndrome - A disease in search of identity, NEUROLOGY, 52(5), 1999, pp. 907-910
Authors:
Zou, LL
Jankovic, J
Rowe, DB
Xie, WJ
Appel, SH
Le, WD
Citation: Ll. Zou et al., Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity, LIFE SCI, 64(15), 1999, pp. 1275-1285
Authors:
Jankovic, J
Lai, E
Ben-Arie, L
Krauss, JK
Grossman, R
Citation: J. Jankovic et al., Levodopa-induced dyskinesias treated by pallidotomy, J NEUR SCI, 167(1), 1999, pp. 62-67
Authors:
Jankovic, J
Schwartz, KS
Ondo, W
Citation: J. Jankovic et al., Re-emergent tremor of Parkinson's disease, J NE NE PSY, 67(5), 1999, pp. 646-650
Authors:
Hanna, PA
Jankovic, J
Vincent, A
Citation: Pa. Hanna et al., Comparison of mouse bioassay and immunoprecipation assay for botulinum toxin antibodies. (vol 66, pg 612, 1999), J NE NE PSY, 67(1), 1999, pp. 133-133
Authors:
Hanna, PA
Jankovic, J
Vincent, A
Citation: Pa. Hanna et al., Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies, J NE NE PSY, 66(5), 1999, pp. 612-616
Authors:
Le, W
Conneely, OM
He, Y
Jankovic, J
Appel, SH
Citation: W. Le et al., Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-Induced injury, J NEUROCHEM, 73(5), 1999, pp. 2218-2221
Authors:
Le, WD
Conneely, OM
Zou, LL
He, Y
Saucedo-Cardenas, O
Jankovic, J
Mosier, DR
Appel, SH
Citation: Wd. Le et al., Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice, EXP NEUROL, 159(2), 1999, pp. 451-458
Authors:
Jankovic, J
Citation: J. Jankovic, New and emerging therapies for Parkinson disease, ARCH NEUROL, 56(7), 1999, pp. 785-790
Authors:
Le, WD
Rowe, DB
Jankovic, J
Xie, WJ
Appel, SH
Citation: Wd. Le et al., Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells, ARCH NEUROL, 56(2), 1999, pp. 194-200
Authors:
Hanna, PA
Jankovic, J
Kirkpatrick, JB
Citation: Pa. Hanna et al., Multiple system atrophy - The putative causative role of environmental toxins, ARCH NEUROL, 56(1), 1999, pp. 90-94
Authors:
Winikates, J
Jankovic, J
Citation: J. Winikates et J. Jankovic, Clinical correlates of vascular parkinsonism, ARCH NEUROL, 56(1), 1999, pp. 98-102
Authors:
Ondo, WG
Hanna, PA
Jankovic, J
Citation: Wg. Ondo et al., Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol, AM J PSYCHI, 156(8), 1999, pp. 1279-1281
Authors:
Wang, WW
Khajavi, M
Patel, BJ
Beach, J
Jankovic, J
Ashizawa, T
Citation: Ww. Wang et al., The G209A mutation in the alpha-synuclein gene is not detected in familialcases of Parkinson disease in non-Greek and/or Italian populations, ARCH NEUROL, 55(12), 1998, pp. 1521-1523